Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study
Crossref DOI link: https://doi.org/10.1007/s00277-016-2668-0
Published Online: 2016-04-22
Published Print: 2016-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mondello, Patrizia
Steiner, Normann
Willenbacher, Wolfgang
Wasle, Ines
Zaja, Francesco
Zambello, Renato
Visentin, Andrea
Mauro, Endri
Ferrero, Simone
Ghione, Paola
Pitini, Vincenzo
Cuzzocrea, Salvatore
Mian, Michael
Text and Data Mining valid from 2016-04-22